Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5-98.1 vs 48% (41.0-57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5-98.2 vs 75.0% (57.8-87.9).
|Number of pages||8|
|Publication status||Published - 15 Jul 2021|
Bibliographical noteFunding Information: This surveillance was internally funded by Public Health England and did not receive any specific grant funding from agencies in the public, commercial or not-for-profit sectors.
Open Access: This work is licensed under a Creative Commons Attribution 4.0 International License.
Publisher copyright: This article is copyright of the authors or their affiliated institutions, 2021.
Citation: Powell Annabel A, Power Linda, Westrop Samantha, McOwat Kelsey, Campbell Helen, Simmons Ruth, Ramsay Mary E, Brown Kevin, Ladhani Shamez N,
Amirthalingam Gayatri. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination,
March−June 2021, England. Euro Surveill. 2021;26(28):pii=2100634.
- COVID-19 vaccine
- heterologous schedule